Verition Fund Management
KROS icon

Verition Fund Management’s Keros Therapeutics KROS Stock Holding History

Verition Fund Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-171,763
Closed -$2.29M – 3895
2025
Q2 		$2.29M Buy
171,763
+130,462
+316% +$1.76M 0.01% 1823
2025
Q1 		$421K Sell
41,301
-174,802
-81% -$2.03M ﹤0.01% 2685
2024
Q4 		$3.42M Buy
+216,103
New +$11.2M 0.01% 1170

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Verition Fund Management's KROS Position: Q3 2025 in Review

Verition Fund Management sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 171,763 shares — an estimated $2.29M sold.

Verition Fund Management first reported a position in KROS in Q4 2024 and held it in 3 quarters. The position peaked at $3.42M in Q4 2024. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • Verition Fund Management reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Verition Fund Management sold 171,763 Keros Therapeutics shares in Q3 2025, an estimated $2.29M.
  • Verition Fund Management first reported a position in Keros Therapeutics in Q4 2024 and held it in 3 quarters.
  • Verition Fund Management's Keros Therapeutics position peaked at $3.42M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on Verition Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.